TY - JOUR
T1 - Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine
AU - Vadiei, Kiumars
AU - Perez-Soler, Roman
AU - Lopez-Berestein, Gabriel
AU - Luke, David R.
N1 - Funding Information:
The present study was supported in part by a grant from the Parenteral Drug Association Foundation and a Biomedical Research Support Grant, administered by the Office of Sponsored Programs, University of Houston. The authors are grateful to Dr. Stuart Feldman for his assistance in the pharmacokinetic analysis.
PY - 1989/12/22
Y1 - 1989/12/22
N2 - The pharmacokinetics and renal toxicity of two liposomal intravenous preparations of cyclosporine (CSA) (A, dimyristoylphosphatidylcholine (DMPC): stearylamine molar ratio 7:1; and B, DMPC: dimyristoylphosphatidylglycerol molar ratio 4:1) were assessed in the murine model and compared to the commercially available intravenous formulation of CSA (IV) and drug-free controls. No significant differences in steady-state area beneath the whole blood concentration-time curves were found between formulations and IV following 10 mg/kg per day CSA for 10 days. However, the apparent volume of distribution was significantly greater in A compared to B or IV formulations (13.82 ± 2.9 vs. 7.23 ± 3.98 and 7.67 ± 3.01 l/kg, p < 0.05), most likely due to the significantly prolonged biologic half-life of this formulation. Although the glomerular filtration rate was not significantly different between A and saline controls (1056 ± 536 and 1130 ± 550 μl/min per g KW, respectively), dosing with B or IV resulted in significant impairment (522 ± 429 and 572 ± 353 μl/min per g kidney weight (KW), respectively; p < 0.05). Triglyceride levels remained unchanged in all groups. However, cholesterol concentrations were significantly increased compared to baseline in rats administered formulation A (98 ± 31 vs. 70 ± 19 mg/dl; p < 0.05). In summary, dosing of liposomal formulation A resulted in equivalent concentrations of CSA as the IV formulation without the dose-limiting nephrotoxicity. These data offer a nontoxic delivery system for intravenous CSA.
AB - The pharmacokinetics and renal toxicity of two liposomal intravenous preparations of cyclosporine (CSA) (A, dimyristoylphosphatidylcholine (DMPC): stearylamine molar ratio 7:1; and B, DMPC: dimyristoylphosphatidylglycerol molar ratio 4:1) were assessed in the murine model and compared to the commercially available intravenous formulation of CSA (IV) and drug-free controls. No significant differences in steady-state area beneath the whole blood concentration-time curves were found between formulations and IV following 10 mg/kg per day CSA for 10 days. However, the apparent volume of distribution was significantly greater in A compared to B or IV formulations (13.82 ± 2.9 vs. 7.23 ± 3.98 and 7.67 ± 3.01 l/kg, p < 0.05), most likely due to the significantly prolonged biologic half-life of this formulation. Although the glomerular filtration rate was not significantly different between A and saline controls (1056 ± 536 and 1130 ± 550 μl/min per g KW, respectively), dosing with B or IV resulted in significant impairment (522 ± 429 and 572 ± 353 μl/min per g kidney weight (KW), respectively; p < 0.05). Triglyceride levels remained unchanged in all groups. However, cholesterol concentrations were significantly increased compared to baseline in rats administered formulation A (98 ± 31 vs. 70 ± 19 mg/dl; p < 0.05). In summary, dosing of liposomal formulation A resulted in equivalent concentrations of CSA as the IV formulation without the dose-limiting nephrotoxicity. These data offer a nontoxic delivery system for intravenous CSA.
KW - Cyclosporine
KW - Liposome
KW - Nephrotoxicity
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=0024843614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024843614&partnerID=8YFLogxK
U2 - 10.1016/0378-5173(89)90300-1
DO - 10.1016/0378-5173(89)90300-1
M3 - Article
AN - SCOPUS:0024843614
SN - 0378-5173
VL - 57
SP - 125
EP - 131
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 2
ER -